AIM — AIM ImmunoTech Share News
0.000.00%
Last trade - 00:00- $8.65m
- $6.99m
- $0.09m
Brief: Aimia Inc Reports Q4 Loss Per Common Share Of $0.32
Brief: AIM ImmunoTech Inc Says Does Not Hold Any Deposits Or Investments At SVB
Brief: AIM ImmunoTech Announces Publication Of New Analysis Of Mechanism Of Action Of Ampligen
Brief: AIM Immuno Tech Enters Into Pancreatic Cancer Research Agreements With Astrazeneca And Erasmus Medical Center
AIM Immunotech gains on research deal for cancer drug study
Brief: Aim Immunotech Broadens Patent Portfolio With New Netherlands Utility Patent Covering Ampligen® And Other Aim-Developed Dsrna Products To Include Rugged Dsrna For Use In Covid-19 Treatment Or Prevention
Brief: Aim Immunotech Broadens Patent Portfolio With New Netherlands Utility Patent Covering Ampligen® And Other Aim-Developed Dsrna Products To Include Rugged Dsrna For Use In Covid-19 Treatment Or Prevention
Brief: AIM ImmunoTech Appoints Christopher McAleer As Scientific Officer
Brief: AIM ImmunoTech Reports Positive Data For Intranasal Ampligen (Rintatolimod)
U.S. RESEARCH ROUNDUP-Analog Devices, Deere & Co, Equifax
Brief: Aim Immunotech Reports Third Quarter 2022 Financial Results
Brief: AIM ImmunoTech Announces Corporate Governance Enhancements
Brief: Aim Immunotech's Ampligen Receives Orphan Drug Designation For Treatment Of Ebola Virus
Brief: Aim Immunotech Stockholder Full Value Committee Provide Statement On Ruling In Delaware Action
Brief: AIM Immunotech Inc Says Delaware Court Rules In Favor Of Co And Declines To Declare Activist Group's Nominations Valid
Brief: Aim Immunotech Board Issues Letter To Shareholders
Brief: ASFV Committee Issues Statement On Aim Immunotech Board
Brief: AIM Immunotech Announces FDA Clearance Of IND Application To Evaluate Ampligen In Phase 2 Clinical Study For Treatment Of Post-Covid Conditions
Brief: Aim Immunotech Board Files Definitive Proxy Statement And Sends Letter To Shareholders